HealthQuill Chronic Kidney Disease
Novo Nordisk has inked a $2 billion licensing pact with United Laboratories International for the development, manufacturing and commercialising of the Chinese company’s “triple G” weight-loss candidate.
Drugs Medical Pharma

Novo Nordisk in $2b deal with Chinese firm for ‘triple-G’ obesity drug

HQ Team February 25, 2025: Novo Nordisk has inked a $2 billion licensing pact with United Laboratories International for the development, manufacturing and.

Read More
FibroGen Inc., a US-based pharmaceutical company, will sell its China subsidiary to AstraZeneca Plc. for $160 million, allowing the Anglo-Swedish firm to gain access to an anaemia drug in the world’s most populated nation.
Drugs Health Pharma

AstraZeneca Plc buys China unit of FibroGen Inc for $160 million

HQ Team February 21, 2025: FibroGen Inc., a US-based pharmaceutical company, will sell its China subsidiary to AstraZeneca Plc. for $160 million, allowing.

Read More
Eli Lilly has stopped trials of its investigational drug to treat chronic kidney disease for a “lack of foreseeable clinical benefit,” according to a company statement.
Drugs Health Medical

Eli Lilly halts trials of investigational chronic kidney disease drug

Eli Lilly has stopped trials of its investigational drug to treat chronic kidney disease for a “lack of foreseeable clinical benefit,” according to.

Read More
Novo Nordisk’s medicine has been approved by the US drug regulator for reducing the risk of kidney failure and death due to cardiovascular disease in diabetic adults with chronic kidney disease.
Drugs Health Medical

Novo’ Nordisk’s drug to cut kidney disease advance in diabetics gets nod

Novo Nordisk’s medicine has been approved by the US drug regulator for reducing the risk of kidney failure and death due to cardiovascular.

Read More
US-based Vertex Pharmaceutical Inc. has signed a licensing pact with China’s Zai Lab Ltd. to develop and commercialise the Boston-headquartered company’s medicine, which is under trial, for treating chronic kidney diseases.
Drugs Health Pharma

Vertex, China’s Zai to develop, commercialise kidney disease drug

US-based Vertex Pharmaceutical Inc. has signed a licensing pact with China’s Zai Lab Ltd. to develop and commercialise the Boston-headquartered company’s medicine, which.

Read More
GLP-1 based weight-loss drugs have some therapeutic benefits, but the risks are as high
Drugs Health Medical Pharma

Novo Nordisk’s Ozempic receives EMA’s nod for chronic kidney disease treatment

HQ Team December 13, 2024: Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP).

Read More
Research uncovers significant discrepancies in ingredient labels and presence of banned compounds
Health

Rosuvastatin may lower mortality compared to atorvastatin: Study

HQ Team November 9, 2024: A recent study indicates that rosuvastatin is associated with a slightly reduced risk of all-cause mortality and major.

Read More
Researchers have found genomic variants in one-third of people from the West African countries of Ghana and Nigeria that significantly increase the risk of developing kidney diseases.
Drugs Health Medical

One-third of West Africans have gene variants causing kidney disease

Researchers have found genomic variants in one-third of people from the West African countries of Ghana and Nigeria that significantly increase the risk.

Read More
British-Swedish AstraZeneca has acquired Amolyt Pharma for $1.05 billion to gain access to Lyon, France-based company’s rare disease, late-stage pipeline.
Drugs Health Pharma

AstraZeneca acquires France’s Amolyt Pharma for $1.05 billion

British-Swedish AstraZeneca has acquired Amolyt Pharma for $1.05 billion to gain access to Lyon, France-based company’s rare disease, late-stage pipeline.

Read More
June 27, 2024: Novo Nordisk’s end-stage trial for hypertension drug has failed to meet its primary goal and the Danish multinational has recognised an impairment loss of 5.7 Danish crowns or $817 million in the second quarter of this year.
Drugs Health Pharma

Novo’s end-stage hypertension trial drug fails, $817m impairment loss

Novo Nordisk’s end-stage trial for hypertension drug has failed to meet its primary goal and the Danish multinational has recognised an impairment loss.

Read More